IRRITABLE BOWEL SYNDROME (IBS) · White paper
Irritable Bowel Syndrome (IBS) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About irritable bowel syndrome (ibs) — and why its trials are hard
Irritable bowel syndrome is a chronic functional gastrointestinal disorder marked by abdominal pain, bloating, and altered bowel habits, with no visible structural abnormality. It affects an estimated 7-15% of the global population (about 10-12% in the U.S.), is roughly twice as common in women, and is subtyped as constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed (IBS-M). Diagnosis rests on symptom-based Rome IV criteria rather than biomarkers. Approved therapies are subtype-specific: linaclotide and lubiprostone for IBS-C, and rifaximin, eluxadoline, and alosetron for IBS-D. Pivotal trials use composite responder endpoints combining abdominal pain reduction (>=30%) with stool-consistency or bowel-movement measures over 12 weeks, assessed with tools such as the Bristol Stool Form Scale and IBS-SSS. The dominant development challenge is a high, variable placebo response that obscures true drug effect, compounded by symptom heterogeneity and inconsistent endpoints. Failed candidates targeting CB2, NK2, and kappa-opioid receptors underscore these hurdles; run-in periods, patient stratification, and standardized validated endpoints are key mitigation strategies.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Linaclotide (Linzess) | 2012 | IBS with constipation (IBS-C) in adults | Pivotal Trials 1 & 2 (e.g., NCT01103236) | Combined abdominal pain + CSBM responder over 12 weeks | Abdominal-pain responders ~34% vs 27% (Trial 1) and 39% vs 20% (Trial 2) vs placebo |
| Rifaximin (Xifaxan) | 2015 (IBS-D) | IBS with diarrhea (IBS-D) in adults | TARGET 1-3 | Adequate relief of IBS symptoms (SGA-IBS) | Adequate relief ~41% vs 31-32% placebo (treatment difference ~8-10%) |
| Eluxadoline (Viberzi) | 2015 | IBS with diarrhea (IBS-D) in adults | Studies 1 & 2 (e.g., NCT01822212) | Composite abdominal pain + stool consistency responder | Composite responders 25-30% (100 mg) vs 16-17% placebo over 12 weeks |
| Lubiprostone (Amitiza) | 2006 (IBS-C in 2008) | IBS with constipation (IBS-C) in adult women | Studies 1 & 2 | Overall responder (global symptom relief) over 12 weeks | Overall responders ~12-14% vs ~6-8% placebo (difference ~6%) |
| Alosetron (Lotronex) | 2000 | Severe IBS-D in women (restricted use under REMS) | Efficacy Studies (e.g., NCT00373020) | Adequate relief of IBS pain/discomfort and urgency | Adequate relief 52% vs 41% placebo at 48 weeks; GIS responders 43-51% vs 31% |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in irritable bowel syndrome (ibs) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| RQ-00202730 (CB2 receptor agonist) — Phase 2 | Discontinued for lack of efficacy in Phase 2 | Difficulty developing CB2 receptor agonists for IBS; high placebo response and symptom heterogeneity |
| Ibodutant (NK2 antagonist) — Phase 3 NAK-06 | Low response and negative results in Phase 3 | Challenges targeting tachykinin NK2 receptor for IBS therapy |
| Fedotozine (kappa-opioid agonist) — Phase 3 | Discontinued after Phase 3 for lack of efficacy | Peripherally selective kappa-opioid receptor agonism did not separate from placebo |
Choosing the right endpoint
Primary endpoints that matter in irritable bowel syndrome (ibs) trials
- Composite responder (pain + stool) — FDA-preferred primary endpoint pairing >=30% abdominal-pain reduction with stool-consistency/CSBM criteria over 12 weeks
- Abdominal pain responder — >=30% reduction in worst/daily abdominal pain on a 0-10 scale for a defined proportion of weeks
- Stool consistency (Bristol Stool Form Scale) — Standardized measure of bowel-habit normalization for IBS-C and IBS-D
- CSBM frequency (IBS-C) — Complete spontaneous bowel movements; captures constipation relief
- IBS Symptom Severity Score (IBS-SSS) / global relief — Validated patient-reported outcome capturing overall symptom burden and adequate relief
How iNGENū runs irritable bowel syndrome (ibs) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Irritable Bowel Syndrome (IBS) clinical trials — FAQs
Why is the placebo response such a problem in IBS trials?
How are IBS drugs matched to patients?
What safety issues shape IBS prescribing?
Ready to discuss your irritable bowel syndrome (ibs) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal